HOME >> BIOLOGY >> NEWS
UT Southwestern researcher, colleagues report drug therapy eases chronic depression

DALLAS Oct. 10, 2002 - A team of scientists representing 12 collaborating health-care centers, including UT Southwestern Medical Center at Dallas, have found that antidepressant therapy specifically sertaline hydrochloride, or Zoloft - can enhance the lives of many chronically depressed patients. The team's findings also showed that discontinuing treatment to patients courts relapse and loss of psychosocial skills.

Dr. John Rush, an internationally known depression researcher who is vice chairman of research in psychiatry at UT Southwestern, said the results send a strong message to health maintenance organizations and insurance companies that deny long-term treatment for a disease that affects millions of Americans. The study, reported in the Archives of General Psychiatry, is the first to systematically look at the long-term impact of depression treatment in the lives of patients and the effects of stopping treatment, said Rush, who was an investigator on the study.

"Chronic depression is an enemy that attacks a person's entire life. The disease incapacitates its victim, laying siege to relationships, educational and vocational success, and even the personal experiencing of joy, pleasure or satisfaction," said Rush.

In all, 635 patients with chronic depression completed 12 weeks of short-term treatment. Those who improved on the Zoloft treatment (209) underwent a four-month continuation trial. Ninety-five percent of those patients responded favorably and were randomized to Zoloft or a placebo for an 18-month maintenance trial. The patients taking Zoloft reported improvement rates of 58 percent to 84 percent on tests qualifying psychosocial dynamics such as functioning, attitudes and quality of life. Only 6 percent of the Zoloft patients relapsed into depression while the placebo group's relapse rate was 23 percent.

Study had either chronic major depression or double depression, a low-level depression disease interrupted by occasio
'"/>

Contact: Ann Harrell
Ann.Harrell@utsouthwestern.edu
214-648-3404
UT Southwestern Medical Center
10-Oct-2002


Page: 1 2

Related biology news :

1. UT Southwestern receives $1.78 million grant for obesity research as part of NIH Roadmap initiative
2. UT Southwestern biochemist honored with NIH Directors Pioneer Award
3. RSV can increase the risk of asthma, UT Southwestern researchers find
4. Searle Scholars program awards $240,000 to UT Southwestern researcher
5. Two molecules work together to aid transport of immune cells, UT Southwestern researchers find
6. Biochemist becomes 15th UT Southwestern faculty member serving on National Academy of Sciences
7. UT Southwestern researchers reveal mechanisms of smooth-muscle contraction
8. Fetal lungs provide a signal initiating labor, UT Southwestern researchers find
9. UT Southwestern researchers cite recent advances in underlying causes of rare body-fat disorders
10. UT Southwestern researchers discover link that could aid in treatment of kidney cyst diseases
11. UT Southwestern research halts narcolepsy symptoms

Post Your Comments:
(Date:5/23/2013)... School of Public Health at Emory University, along ... have received a $4 million grant over four ... University (Health and Exposome Research Center: Understanding Lifetime ... grant awarded in the United States. , ... Institute of Environmental Health Sciences (NIEHS) of the ...
(Date:5/23/2013)... new report from the Institute of Medicine says schools ... least 60 minutes of vigorous or moderate intensity activity ... of American youth meet current evidence-based guidelines of at ... activity daily, according to the report, which was released ... nearly half of their waking hours, the committee recommends ...
(Date:5/23/2013)... when microbial pathogens are growing increasingly resistant to the ... of Wisconsin scientists has synthesized a potent new class ... staph infections. , Writing online in the Journal ... by University of Wisconsin-Madison chemistry Professor Helen Blackwell describes ... of Staphylococcus aureus , a bacterium at the ...
Breaking Biology News(10 mins):Emory, Georgia Tech receive first human exposome center grant in US 2Emory, Georgia Tech receive first human exposome center grant in US 3Schools should provide students with daily physical activity, IOM recommends 2University of Wisconsin chemists find new compounds to curb staph infection 2
(Date:5/24/2013)... May 24, 2013 Vestiage, Inc. ... company focused on science-based research and development, sales ... cosmeceuticals and nutraceuticals, announced today that it is ... for the sale of Reluma Skin Illuminating Facial ... and application by sending an email to info(at)vestiageinc(dot)com ...
(Date:5/23/2013)... May 23, 2013 Venaxis, Inc. (Nasdaq:   ... on obtaining FDA clearance and commercializing its rapid, protein ... pricing of an underwritten public offering of 10,000,000 shares ... 3,500,000 shares of its common stock at an exercise ... offering price of $1.25 per share and related warrant.  ...
(Date:5/23/2013)... Patheon Inc ., a leading ... global pharmaceutical industry, will host a complimentary webinar on ... on Tuesday, June 4, 2013 at 11 a.m. Eastern ... to comply with regulations for cleaning validation. Many ... underpinning and little evaluation of risk. Some companies ...
(Date:5/23/2013)... 23, 2013 PI’s new LPS-24 ... provide 15 mm travel range with closed-loop sensor ... dimensions make these new positioners the ideal choice ... vacuum rated version is also available. , ... datasheets can be found at: , http://www.physikinstrumente.com/en/products/prdetail.php?sortnr=1000745&prw-lps24 ...
Breaking Biology Technology:Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 2Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 3Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 4Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 5Venaxis Announces Pricing of Offering of Common Stock and Warrants 2Venaxis Announces Pricing of Offering of Common Stock and Warrants 3Patheon to Present on “Cleaning Validation: Science, Risk and Novel Approaches to Testing” 2Precision Positioning System Uses Miniaturezed Piezo Linear Motor: LPS-24 Linear Stage by PI 2
Cached News: